We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Crystal Structures Define Mode of Action of Bacteriophage Endolysins

By LabMedica International staff writers
Posted on 13 Aug 2014
New antibacterial agents based on bacteriophages or their endolysin enzymes have been proposed to solve the problem of the bacterium Clostridium difficile, which is becoming a serious health hazard in hospitals and healthcare institutes, due to its resistance to antibiotics.

Investigators at the European Molecular Biology Laboratory (Hamburg, Germany) based their research primarily on the bacteriophage CD27, which is capable of lysing C. More...
difficile. In addition, they worked with a recombinant form of the CD27L endolysin, which lyses C. difficile in vitro.

To better understand how the lysis process works, the investigators determined the three-dimensional structures of the CD27L endolysin and the CTP1L endolysin from the closely related bacteriophage CPT1 that targets C. tyrobutyricum. For this task they employed X-ray crystallography and small angle X-ray scattering (SAXS), which was done at the Deutsches Elektronen-Synchrotron (DESY).

Results published in the July 24, 2014, online edition of the journal PLOS Pathogens revealed that the two endolysins shared a common activation mechanism, despite having been taken from different species of Clostridium. The activation mechanism depended on a structure where an extended dimer existed in the inactive state but switched to a side-by-side "relaxed" morphology in the active state, which triggered the cleavage of the C-terminal domain. This change of morphology led to the release of the catalytic portion of the endolysin, enabling the efficient digestion of the bacterial cell wall.

“These enzymes appear to switch from a tense, elongated shape, where a pair of endolysins is joined together, to a relaxed state where the two endolysins lie side-by-side,” said first author Dr. Matthew Dunne, a researcher at the European Molecular Biology Laboratory. “The switch from one conformation to the other releases the active enzyme, which then begins to degrade the cell wall.”

Related Links:

European Molecular Biology Laboratory



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Immunofluorescence Analyzer
IFA System
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.